Silexion Therapeutics Corp (SLXN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.14M
Last updated: Nov 17, 2026 at 4:11 PM ET
Silexion Therapeutics Corp (SLXN) Statistics
Silexion Therapeutics (SLXN) has a market cap of $1.14M. It kept -24052.73% of revenue as net income over the last 12 months. It holds $4.76M more cash than debt, 416.38% of its market cap.
Total Valuation
| Market Cap | $1.14M |
|---|---|
| Latest price (Nov 17, 2026) | $1.65 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.5x and 0.1x.
| P/S Ratio | 5.5x |
|---|---|
| P/B Ratio | 0.1x |
Price Statistics
The stock is down 99.76% over 52 weeks and trades 69.61% below its 50-day average.
| Beta (1Y) | 3.26 |
|---|---|
| 52-Week Change | -99.76% |
| 1-Month Change | -55.07% |
| 3-Month Change | -83.36% |
| 6-Month Change | -97.44% |
| Total Return (1Y) | -99.76% |
| Return vs SPY (1Y) | -111.29% |
| Max Drawdown (1Y) | -99.78% |
| Max Drawdown (3Y) | -100.00% |
| Sharpe Ratio (1Y) | -3.25 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $5.43 |
| 200-Day Average | $130.59 |
| 52-Week Range | $1.74 to $777.12 |
| RSI (14 Days) | 27.0 |
| Average Volume (20 Days) | 647.79K |
Financial Position
Current assets cover 1.66x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.66x |
|---|---|
| Quick Ratio | 1.66x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -445.72% and return on assets is -193.77% over the last 12 months.
| Return on Equity (ROE) | -445.72% |
|---|---|
| Return on Assets (ROA) | -193.77% |
| Return on Capital Employed (ROCE) | -418.12% |
| Asset Turnover | 0.01x |
Scores
SLXN has an Altman Z-Score of -19.00, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -19.00 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $55.00K over the last 12 months is up 83.33% from the 12 months before.
| Revenue | $55.00K |
|---|---|
| Revenue Growth (YoY) | +83.33% |
| Gross Profit | $55.00K |
| Operating Income | -$13.43M |
| Pretax Income | -$13.23M |
| Net Income | -$13.23M |
| EBITDA | -$13.14M |
| EBIT | -$13.15M |
| Reported EPS (TTM) | -$41.48 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.48% of the $6.83M in total assets.
| Cash and Equivalents | $4.76M |
|---|---|
| Total Debt | $0 |
| Net Cash | $4.76M |
| Net Cash Per Share | $25.74 |
| Working Capital | $2.43M |
| Shareholder Equity | $2.97M |
| Book Value Per Share | $16.05 |
| Total Assets | $6.83M |
| Total Liabilities | $3.86M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$11.70M |
|---|---|
| FCF Per Share | -$18.52 |
| Depreciation and Amortization | $10.00K |
| Share Repurchases | $490.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -24425.45%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -24425.45% |
| Pretax Margin | -24052.73% |
| Net Margin | -24052.73% |
| EBITDA Margin | -23898.18% |
| EBIT Margin | -23916.36% |
Dividends and Yields
SLXN does not pay a dividend.
| Buyback Yield | -986.14% |
|---|---|
| Shareholder Yield | -986.14% |
Stock Splits
The last split was a 1-for-24 reverse split on Nov 11, 2026.
| Last Split Date | Nov 11, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:24 |
Peer Position
Against 4 similar companies, SLXN has the 3rd highest P/S.
P/S RatioPeer median 8.7x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +112.34%
| P/S Ratio | 5.5x vs 8.7x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +83.33% vs +112.34% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SLXN
What is SLXN's market cap?
Silexion Therapeutics has a market cap of $1.14M.
How many shares of SLXN are outstanding?
Silexion Therapeutics has 184.93K shares outstanding.
Does SLXN pay a dividend?
No. Silexion Therapeutics does not pay a dividend.
How much debt does SLXN have?
Silexion Therapeutics has $0 of total debt and $4.76M of cash and equivalents, a net cash position of $4.76M.
SLXN pages: Overview, Charting, Forecast, Financials, Statistics, Competitors